Articles from Elion Therapeutics

Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection
- Turletricin Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA -
By Elion Therapeutics · Via GlobeNewswire · April 15, 2026
Articles from Elion Therapeutics | WAOW